Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy
October 28th 2024Panelists discuss the strategies they employ to manage adverse events in patients starting capivasertib, including minimizing the risk of diarrhea through dietary considerations and patient education, as well as approaches for monitoring and managing rash associated with the treatment and providing education about it.
Read More
Overview of the CAPItello-291 Trial
October 21st 2024Panelists discuss the findings of the CAPItello-291 trial, which investigated capivasertib combined with fulvestrant in advanced hormone receptor–positive, HER2-negative breast cancer, leading to its approval in November 2023 and highlighting its potential as a new targeted therapy option in the second-line setting due to the prevalence of PIK3CA, AKT1, and PTEN alterations.
Read More
Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer
October 21st 2024Panelists discuss how aberrations in the PI3K/AKT/PTEN pathway drive treatment resistance and disease progression following first-line therapy in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the critical role of repeat biomarker testing to guide ongoing treatment strategies and enhance patient outcomes.
Read More
Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer
October 14th 2024Panelists discuss how biomarker testing plays a critical role in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the timing of testing, the relevance of specific genomic assays, and the significant impact on prognosis and treatment decisions.
Read More
Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.
Read More
Neoadjuvant Treatment Options in HER2+ Early Breast Cancer
Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.
Read More
Challenges in Diagnosing HER2+ Breast Cancer
A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.
Read More